Editorial Team

Research articles are drafted and reviewed by the Remy Research editorial team. Bylines read “Remy Research Editorial Team” and review lines read “Reviewed by Remy Research Editorial Board”; both labels name Remy Research’s own editorial work, not an outside organisation.

Remy Research does not publish the names or qualifications of individual writers and reviewers, so this page names no individuals and lists no credentials. The site names no independent clinical or medical reviewer. Articles are written under the For Research Use Only standard set out in the editorial policy.

• Drafting — the editorial team drafts each article from primary and peer-reviewed sources.
• Internal review — every numerical claim is cross-checked against the cited document before sign-off.
• Editorial sign-off — the editorial team verifies scientific accuracy, regulatory-status accuracy, compliance wording, and consistency with the rest of the library.
• Post-publication monitoring — articles are re-reviewed when new clinical data, regulatory decisions, broken citations, or reader reports trigger an update, and material changes are logged in the article’s Update History.

Source rules are in the research standards.

Remy Research sells research-use-only peptides, including retatrutide, and the editorial team is part of Remy Research. The library also covers compounds Remy Research does not sell, and the same sourcing and verification standards apply regardless of commercial interest.

To report an error on a research page, use the contact page; how corrections are handled and logged is set out in the editorial policy.